These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27409299)

  • 1. Glutamate-Based Drug Discovery for Novel Antidepressants.
    Pałucha-Poniewiera A; Pilc A
    Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
    Musazzi L
    Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
    Dogra S; Conn PJ
    Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mGlu receptors as potential targets for novel antidepressants.
    Chaki S; Fukumoto K
    Curr Opin Pharmacol; 2018 Feb; 38():24-30. PubMed ID: 29486373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGlu2/3 receptor as a novel target for rapid acting antidepressants.
    Chaki S
    Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
    Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
    Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 12. Glutamate-based antidepressants: preclinical psychopharmacology.
    Pilc A; Wierońska JM; Skolnick P
    Biol Psychiatry; 2013 Jun; 73(12):1125-32. PubMed ID: 23453290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mGlu2/3 Receptor Antagonists as Novel Antidepressants.
    Chaki S
    Trends Pharmacol Sci; 2017 Jun; 38(6):569-580. PubMed ID: 28413097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
    Onisiforou A; Georgiou P; Zanos P
    Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rapid-onset antidepressant effect of ketamine: More surprises?
    Raffa RB; Pergolizzi JV; Taylor R;
    J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
    Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
    Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.